drugset / Trial / NCT04236414

Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours

NCT04236414

Phase 1 Completed 16 enrolled AstraZeneca
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents with solid tumours.

Timeline

Start
2020-01-14
Primary completion
2025-02-04
Completion
2025-02-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Olaparib Small molecule 15 mg Oral
Subject Olaparib Small molecule 19.5 mg Oral
Subject Olaparib Small molecule 25 mg Oral
Subject Olaparib Small molecule 100 mg Oral

Indications